

# Susan L Uprichard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/330632/publications.pdf>

Version: 2024-02-01

37  
papers

3,451  
citations

430874

18  
h-index

330143

37  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3712  
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust hepatitis C virus infection <i>in vitro</i> . Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9294-9299.	7.1	1,597
2	Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3991-3996.	7.1	298
3	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases, The, 2015, 15, 1167-1174.	9.1	216
4	Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 773-778.	7.1	212
5	Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10777-10782.	7.1	177
6	The therapeutic potential of RNA interference. FEBS Letters, 2005, 579, 5996-6007.	2.8	142
7	Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures. Journal of Virology, 2002, 76, 5646-5653.	3.4	119
8	Replication of a hepatitis C virus replicon clone in mouse cells. Virology Journal, 2006, 3, 89.	3.4	85
9	Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1310-1315.	7.1	71
10	HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. Journal of Hepatology, 2016, 64, 1232-1239.	3.7	65
11	Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon. Journal of Virology, 2009, 83, 6383-6390.	3.4	56
12	Determining the Involvement and Therapeutic Implications of Host Cellular Factors in Hepatitis C Virus Cell-to-Cell Spread. Journal of Virology, 2014, 88, 5050-5061.	3.4	38
13	Unexpected Structural Features of the Hepatitis C Virus Envelope Protein 2 Ectodomain. Journal of Virology, 2014, 88, 10280-10288.	3.4	37
14	Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. Journal of Virology, 2015, 89, 6551-6561.	3.4	32
15	Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology, 2018, 68, 473-484.	7.3	30
16	Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Research, 2017, 144, 281-285.	4.1	26
17	Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Scientific Reports, 2020, 10, 7837.	3.3	24
18	Accounting for Space-Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models. Viruses, 2018, 10, 200.	3.3	22

#	ARTICLE	IF	CITATIONS
19	The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?. <i>Scientific Reports</i> , 2017, 7, 10233.	3.3	20
20	Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. <i>Scientific Reports</i> , 2020, 10, 17820.	3.3	20
21	HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. <i>PLoS ONE</i> , 2017, 12, e0187409.	2.5	19
22	The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. <i>Virology</i> , 2010, 407, 110-119.	2.4	17
23	Cell-Based Hepatitis C Virus Infection Fluorescence Resonance Energy Transfer (FRET) Assay for Antiviral Compound Screening. <i>Current Protocols in Microbiology</i> , 2010, 18, Unit 17.5..	6.5	15
24	Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 68-73.	3.2	15
25	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019, 39, 826-834.	3.9	15
26	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. <i>Viruses</i> , 2021, 13, 1743.	3.3	15
27	Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. <i>Journal of Virology</i> , 2021, 95, e0049220.	3.4	14
28	Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration. <i>Journal of Infectious Diseases</i> , 2020, 222, 1165-1169.	4.0	10
29	HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics. <i>Viruses</i> , 2021, 13, 1308.	3.3	9
30	Hepatitis C virus Cell-to-cell Spread Assay. <i>Bio-protocol</i> , 2014, 4, .	0.4	7
31	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2019, 163, 149-155.	4.1	6
32	Modeling based response guided therapy in subjects with recent hepatitis C infection. <i>Antiviral Research</i> , 2020, 180, 104862.	4.1	6
33	Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment. <i>Gut</i> , 2015, 64, 690-691.	12.1	5
34	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. <i>Viruses</i> , 2022, 14, 370.	3.3	5
35	Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. <i>ELife</i> , 2021, 10, .	6.0	4
36	Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection. <i>Hepatology</i> , 2014, 59, 2043-2046.	7.3	1

#	ARTICLE	IF	CITATIONS
37	Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. <i>Viruses</i> , 2019, 11, 263.	3.3	1